Hy's Law: predicting serious hepatotoxicity

被引:261
作者
Temple, R [1 ]
机构
[1] US FDA, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA
关键词
D O I
10.1002/pds.1211
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
引用
收藏
页码:241 / 243
页数:3
相关论文
共 4 条
[1]   A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience [J].
Goldkind, L ;
Laine, L .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 (04) :213-220
[2]   Hepatic findings in long-term clinical trials of ximelagatran [J].
Lee, WM ;
Larrey, D ;
Olsson, R ;
Lewis, JH ;
Keisu, M ;
Auclert, L ;
Sheth, S .
DRUG SAFETY, 2005, 28 (04) :351-370
[3]   Hy's law [J].
Reuben, A .
HEPATOLOGY, 2004, 39 (02) :574-578
[4]  
TEMPLE R, 2000, DRUG INDUCED LIVER T